Crenolanib is a selective type I pan-FLT3 inhibitor

Tyrosine kinase inhibitors (TKIs) represent transformative therapies for several malignancies. Two critical features necessary for maximizing TKI tolerability and response duration are kinase selectivity and invulnerability to resistance-conferring kinase domain (KD) mutations in the intended target...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Smith, Catherine Choy, Lasater, Elisabeth A., Lin, Kimberly C., Wang, Qi, McCreery, Melissa Quino, Stewart, Whitney K., Damon, Lauren E., Perl, Alexander E., Jeschke, Grace R., Sugita, Mayumi, Carroll, Martin, Kogan, Scott C., Kuriyan, John, Shah, Neil P.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2014
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3986131/
https://ncbi.nlm.nih.gov/pubmed/24623852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1320661111
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados